AFCG vs FSP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AFCG exhibits severe financial distress signals, with a Piotroski F-Score of 2/9 indicating poor operational and financial health. The company reports a negative ROE of -10.97%, a negative operating margin of -43.96%, and a payout ratio of 152.22%, suggesting unsustainable dividend payments. Despite a 120.1% YoY revenue growth, earnings remain volatile and unprofitable, with a history of massive negative earnings surprises. The lack of an Altman Z-Score and the absence of reliable cash flow and debt metrics further compound the risk. The stock trades at a 31.37 Price/Sales ratio, far above peers, and is down 56.7% over the past year, reflecting deteriorating investor sentiment.
FSP exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a total lack of positive technical momentum (0/100). The company is suffering from a secular decline in the Office REIT sector, evidenced by massive realized losses on property divestitures in Atlanta and Indianapolis. While the Price-to-Book ratio of 0.11 suggests deep value, the 10-K reveals that assets are being sold at significant discounts, implying that book value is heavily inflated and impaired. Consistent earnings misses and negative profit margins further solidify a bearish outlook.
Compare Another Pair
Related Comparisons
AFCG vs FSP: Head-to-Head Comparison
This page compares Advanced Flower Capital Inc. (AFCG) and Franklin Street Properties Corp. (FSP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.